دورية أكاديمية

Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer : a retrospective study of case analysis.

التفاصيل البيبلوغرافية
العنوان: Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer : a retrospective study of case analysis.
المؤلفون: Chao-Wen Hsu, Tai-Ming King, Chieh-Hsin Lin, Hsin-Tai Wang, Wen-Chieh Ou, Jui-Ho Wang
المصدر: International Journal of Colorectal Disease; Apr2009, Vol. 24 Issue 4, p377-383, 7p, 1 Black and White Photograph, 4 Charts
مصطلحات موضوعية: COLON cancer treatment, CANCER patients, DRUG therapy, OXALIPLATIN, METASTASIS, CONTROL groups
مستخلص: Conventional use of FOLFIRI–FOLFOX or the reverse sequence is the optional regimen in metastatic unresectable colorectal cancer (CRC). We present our experience in chemotherapy (C/T) shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing regimens. A total of 48 patients with metastatic unresectable CRC were examined retrospectively. All the patients had both failure of a first-line C/T and a second-line C/T. Of these patients, 13 patients received C/T shifting to first-line regimen. Data were collected retrospectively. Rate of disease control of 38.4% was achieved (five in 13 patients). In the positive disease control group, metastatic sites were all extra-hepatic (five patients). In the negative disease control group, hepatic metastatic rate was 62.5% (five in eight patients, P = 0.044). Even after previous failure of irinotecan and oxaliplatin containing C/T, we observe positive disease control response and survival benefit in selected patients with C/T shifting to the first-line regimen especially in extra-hepatic metastasis. The preliminary results are proposed to gain insight into the need for further investigations and large-scale studies. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Colorectal Disease is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:01791958
DOI:10.1007/s00384-008-0621-y